Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 in advanced or metastatic renal cell carcinoma
jRCT2021250044Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of PF-08634404 in renal cell carcinoma (RCC) (3 arms), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate (ORR) per RECIST v1.1, Number of participants with treatment-emergent adverse events (AEs) and serious adverse events (SAEs) and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2021250044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250044.